Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-002125-30
    Sponsor's Protocol Code Number:AELIX-003
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Restarted
    Date on which this record was first entered in the EudraCT database:2018-11-16
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2018-002125-30
    A.3Full title of the trial
    A Phase IIa, randomized, double-blind, placebo-controlled, study of HIV-1 Vaccines MVA.HTI and ChAdOx1.HTI with TLR7 agonist vesatolimod (GS-9620), in early treated HIV-1 infection
    Estudio de fase IIa aleatorizado, doble ciego y controlado con placebo de las vacunas contra el VIH 1 MVA.HTI y ChAdOx1.HTI con el agonista del receptor TLR7 vesatolimod (GS-9620) en la infección por el VIH-1 tratada de forma precoz.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to evaluate how safe MVA.HTI and ChAdOx1.HTI vaccines with vesatolimod are in participants with early treated HIV-1 infection.
    Un estudio para evaluar la seguridad de las vacunas MVA.HTI y ChAdOx1.HTI con vesatolimod en sujetos participantes con infección por VIH-1 tratados de forma precoz.
    A.4.1Sponsor's protocol code numberAELIX-003
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAELIX Therapeutics
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAELIX Therapeutics
    B.4.2CountrySpain
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAELIX Therapeutics
    B.5.2Functional name of contact pointAnne Leselbaum
    B.5.3 Address:
    B.5.3.1Street AddressBaldiri i Reixac, 4-8
    B.5.3.2Town/ cityBarcelona
    B.5.3.3Post code08028
    B.5.3.4CountrySpain
    B.5.4Telephone number34934031339
    B.5.6E-mailclinical@aelixtherapeutics.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMVA.HTI
    D.3.2Product code MVA.HTI
    D.3.4Pharmaceutical form Suspension for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntramuscular use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMVA.HTI
    D.3.9.2Current sponsor codeMVA.HTI
    D.3.9.4EV Substance CodeSUB183857
    D.3.10 Strength
    D.3.10.1Concentration unit PFU plaque forming unit
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200000000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms Yes
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameChAdOx1.HTI
    D.3.2Product code ChAdOx1.HTI
    D.3.4Pharmaceutical form Suspension for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntramuscular use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCHADOX1.HTI
    D.3.9.2Current sponsor codeCHADOX1.HTI
    D.3.9.3Other descriptive nameCHADOX1.HTI
    D.3.9.4EV Substance CodeSUB194136
    D.3.10 Strength
    D.3.10.1Concentration unit billion organisms billion organisms
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms Yes
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameVesatolimod
    D.3.2Product code GS-9620
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNVESATOLIMOD
    D.3.9.2Current sponsor codeGS-9620
    D.3.9.4EV Substance CodeSUB193598
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboIntramuscular use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Human immunodeficiency virus type 1
    Virus de inmunodeficiencia humana tipo 1
    E.1.1.1Medical condition in easily understood language
    Human immunodeficiency virus (HIV)
    Virus de inmunodeficiencia humana (VIH)
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level PT
    E.1.2Classification code 10020161
    E.1.2Term HIV infection
    E.1.2System Organ Class 10021881 - Infections and infestations
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the safety of the CCMM (ChAdOx1.HTI + MVA.HTI) + Vesatolimod regimen during Period 1 (week 0 to 48) in early treated HIV 1 infection
    Evaluar la seguridad del tratamiento con CCMM y vesatolimod durante el periodo 1 (semanas 0 a 48) para la infección por el VIH 1 tratada de forma precoz.
    E.2.2Secondary objectives of the trial
    Safety
    •To evaluate the safety of the CCMM + Vesatolimod regimen after period 1 in early treated HIV-1 infection

    Efficacy
    •To evaluate whether CCMM + vesatolimod is able to prevent or delay viral rebound, induce post-rebound viral control, and/or prevent or delay the need for resumption of antiretroviral therapy (ART) following an analytical treatment interruption (ATI) in early treated HIV-1 infection
    Immunogenicity
    •To evaluate the immunogenicity of CCMM + vesatolimod in early treated HIV-1 infection
    Seguridad
    -Evaluar la seguridad del tratamiento con CCMM y vesatolimod después del periodo 1 para la infección por el VIH-1 tratada de forma precoz.
    Eficacia
    -Evaluar si CCMM y vesatolimod son capaces de prevenir o retrasar el rebote vírico, inducir el control vírico tras el rebote o prevenir o retrasar la necesidad de reanudar el tratamiento antirretrovírico (TAR) después de una ITA en la infección por el VIH-1 tratada de forma precoz.
    Inmunogenicidad
    Evaluar la inmunogenicidad de CCMM y vesatolimod en la infección por el VIH-1 tratada de forma precoz.
    E.2.3Trial contains a sub-study No
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Subestudio del tejido linfático asociado al intestino (TLAI): Se realizará un subestudio opcional para determinar el fenotipo / activación de células inmunitarias, la expresión de genes (incluidos los ISGs), las respuestas de células T específicas para VIH-1 y el reservorio de VIH-1 en TLAI en centros seleccionados para aquellos participantes que firmen un ICF separado y dispuestos a someterse a una sigmoidoscopia flexible, incluyendo la recolección de aproximadamente 20 biopsias rectales.
    E.3Principal inclusion criteria
    1.Understands the study information provided and is capable of giving written informed consent.
    2.Has confirmed HIV-1 infection
    3.Has received ART, defined as ≥3 antiretroviral drugs, that was initiated within 6 months of the estimated date of HIV-1 acquisition. The ART regimen is required to have included ≥3 antiretroviral drugs at the time of treatment initiation and is required to include ≥3 antiretroviral drugs at screening, but temporary use of a 2drug ART regimen during the time between ART initiation and the screening visit is permitted.
    4.Has plasma HIV-1 RNA levels <50 copies/mL at the screening visit and has been virologically suppressed, defined as pVL <50 copies/mL, for at least 1 year before the screening; isolated blips allowed (<200 copies/mL, non consecutive, representing <10% of total determinations or ocurrence less than or equal to twice per year).
    5.Has documented stable CD4 counts ≥450 cells/mm3 for the 6 months before the screening and at the screening visit.
    6.Has nadir CD4 count ≥200 cells/mm3 since human immunodeficiency virus HIV diganosis.
    7.Is ≥18 and <61 years of age on the day of the screening visit
    8.Is willing to comply with all study procedures, including the ATI, collection of blood samples per the protocol and adherence to ART regimen, and is available for the planned duration of the study
    9.If heterosexually active female and of childbearing potential, must be using highly effective methods of contraception from 14 days before the first vaccination until the end of the study (or 40 days after the last dose of vesatolimod, whichever is later); all female volunteers must be willing to undergo urine pregnancy testing.
    10. If heterosexually active male, must use condoms or practice sexual abstinence from the screening visit until the end of the study (or 100 days after the last dose of vesatolimod, whichever is later). Female partners of male participants must be using highly effective methods of birth control from the screening visit to the end of the study.
    1.Entiende la información del estudio que se le ha facilitado y es capaz de otorgar el consentimiento informado por escrito, de acuerdo con el investigador o la persona designada.
    2.Infección por el VIH-1 confirmada.
    3.Ha recibido TAR, definido como ≥ 3 antirretrovíricos que se iniciaron en los 6 meses siguientes a la fecha estimada de adquisición del VIH-1. La pauta de TAR deberá haber incluido ≥ 3 antirretrovíricos en el momento de iniciar el tratamiento y deberá incluir ≥ 3 antirretrovíricos en la selección, pero se permitirá el uso temporal de una pauta de TAR de 2 fármacos durante el tiempo transcurrido entre el inicio del TAR y la visita de selección.
    4.Presenta niveles plasmáticos de ARN del VIH-1 <50 copias/ml en la visita de selección y ha presentado supresión virológica, definida como CVP <50 copias/ml, durante al menos 1 año antes de la selección, permitiéndose elevaciones ligeras de la concentración vírica de forma aislada (<200 copias/ml, no consecutivas, que representen <10% de todas las determinaciones o menos de o igual a dos episodios por año).
    5.Presenta recuentos estables documentados de CD4 ≥450 células/mm3 durante los 6 meses previos a la selección y en la visita de selección.
    6.Presenta un recuento mínimo de CD4 ≥200 células/mm3 desde el diagnóstico del virus de la inmunodeficiencia humana (VIH); solo se permitirán recuentos inferiores aislados en el momento de la infección aguda por el VIH-1 si se ha seguido una recuperación inmunitaria adecuada tras el inicio del TAR (véase el criterio de inclusión n.º 5).
    7.Tiene ≥18 años y <61 años el día de la selección.
    8.Está dispuesto a cumplir todos los procedimientos del estudio, incluidas las ITA, la obtención de muestras de sangre conforme al protocolo y el cumplimiento terapéutico del TAR, y está disponible durante el periodo previsto del estudio.
    9.Las mujeres con actividad heterosexual y que estén en edad fértil deberán utilizar métodos anticonceptivos muy eficaces, como se detalla en Apéndice 2, desde 14 días antes de la primera vacuna hasta el final del estudio (o 40 días después de la
    última dosis de vesatolimod, lo que suceda más tarde); todas las voluntarias deberán estar dispuestas a someterse a pruebas de embarazo en orina en los momentos especificados en el calendario de actividades (Apéndice 1).
    •Las mujeres participantes que utilicen anticonceptivos hormonales como uno de los métodos anticonceptivos deben haber usado el mismo método durante al menos 3 meses antes de la primera vacuna.
    •Las mujeres que lleven sin menstruación ≥12 meses, sin constancia de una insuficiencia hormonal ovárica, deberán tener una concentración sérica de folitropina (FSH) en la selección que esté dentro del intervalo posmenopáusico, como se indica en el manual del laboratorio central.
    10.Si es hombre con actividad heterosexual, deberá utilizar preservativo o practicar la abstinencia sexual desde la visita de selección hasta el final del estudio. Las parejas femeninas de los participantes varones deberán utilizar métodos anticonceptivos muy eficaces desde la visita de selección hasta el final del estudio (o 100 días después de la última dosis de vesatolimod, lo que ocurra más tarde).
    E.4Principal exclusion criteria
    1. Is pregnant or lactating at the screening visit or is planning on becoming pregnant over the duration of the study
    2. If available, has genotypic data (e.g., HIV genotype data) that demonstrate the presence of clinically significant mutations that would prevent the construction of a viable ART regimen post-treatment interruption
    3. Has reported multiple (consult with medical monitor) periods of suboptimal adherence to ART.
    4. Has a history of past ART interruptions lasting longer than 2 weeks
    5. Has participated in another interventional clinical study within 30 days before the screening visit
    6. Has any acquired immune deficiency syndrome (AIDS) defining disease or progression of HIV related disease within 90 days of the screening visit
    7. Has a history of any moderate and/or severe autoimmune disease (consult with medical monitor).
    8. Has a history or clinical manifestations of any physical or psychiatric disorder that could impair the participant’s ability to complete the study
    9. Is taking HIV protease inhibitors (including low-dose ritonavir), cobicistat-containing regimens, elvitegravir, efavirenz, etravirine or nevirapine. Participants on prohibited ART medications will be allowed to switch to an accepted treatment between screening and baseline; participants must be on the new ART regimen at least 14 days prior to the collection of screening laboratory samples. The baseline visit should be completed once all screening laboratory results are available and reviewed.
    10. Is taking any other concomitant treatments non compatible with vesatolimod before starting treatment in the study. Participants on non compatible medications at screening (e.g., atorvastatin) will be allowed to switch treatments; participants who switch medications must be stopped at least 30 days prior to the first dose of vesatolimod.
    11. Has received approved vaccines within 2 weeks of study entry or has had a previous immunisation with any experimental immunogens within the previous 2 years.
    12. Will receive any vaccines within 4 weeks prior to, or 2 weeks after any of the planned CCMM administrations or on a week when vesatolimod is administered
    13. Has a history of anaphylaxis or a severe adverse reaction to vaccines
    14. Has received blood products within 6 months of the screening visit
    15. Has received treatment for cancer or lymphoproliferative disease within 1 year of screening
    16. Has received any other current or prior therapy within 30 days prior to the screening visit that, in the opinion of the investigators and/or the sponsor, would make the participant unsuitable for the study or influence the results of the study.
    17. Has current or has had recent use (within last 3 months before the screening visit) of IFN or systemic corticosteroids or other immunosuppressive agents (use of inhaled steroids for pulmonary conditions or topic steroids for localised skin conditions is permitted)
    18. Have abnormalities of haematology, clinical chemistry and microbiology as below
    • Haemoglobin <11 g/dL (females) or 11.5 g/dL (males)
    •Absolute neutrophil count ≤1000/mm3 (≤1 ×10^9/L)
    •Absolute lymphocyte count ≤600/mm3 (≤0.6 ×10^9/L)
    •Platelets ≤100,000/mm3 or ≥550,000/mm3 (≤100 x10^3/µL or ≥550x10^3/µL)
    Clinical Chemistry
    •Creatinine >1.3 × upper limit of normal (ULN)
    •Aspartate aminotransferase >2.5 × ULN
    •Alanine aminotransferase >2.5 × ULN
    Microbiology
    •Positive hepatitis B surface antigen
    •Positive for hepatitis C antibody, unless confirmed clearance of hepatitis C virus infection determined by negative hepatitis C virus polymerase chain reaction.
    •Positive serology indicating active syphilis requiring treatment; participants with positive rapid plasma reagin titres detected at screening should be treated and retested before the baseline visit. The screening period may be extended up to 45 days should accommodate participants being treated for syphilis.
    19.Is unwilling to undergo an ATI as planned during the study.
    20.Is not suitable for inclusion in the study based on the judgment of the investigator or sponsor.
    21.Current alcohol, drug, or substance abuse or history of such abuse within the 6 months prior to screening.
    1.Está embarazada o en periodo de lactancia en la visita de selección o en cualquier momento del estudio o tiene previsto quedarse embarazada durante el estudio.
    2.Si están disponibles, tiene datos genotípicos (p. ej., datos del genotipo del VIH) que demuestran la presencia de mutaciones clínicamente significativas que podrían impedir la construcción de una pauta de TAR factible después de la interrupción del tratamiento.
    3.Ha comunicado multiples (consultar con el monitor médico) periodos de cumplimiento insuficiente del TAR
    4.Tiene antecedentes de interrupciones previas del TAR conocidos durante más de 2 semanas.
    5.Ha participado en otro estudio clínico intervencionista en los 30 días previos a la selección.
    6.Presenta cualquier enfermedad definitoria del síndrome de inmunodeficiencia adquirida o progresión de una enfermedad relacionada con el VIH en los 90 días previos a la visita de selección.
    7.Tiene antecedentes de cualquier enfermedad autoinmunitaria moderada o grave (consultar con el monitor médico).
    8.Tiene antecedentes o manifestaciones clínicas de cualquier trastorno físico o psiquiátrico que puedan afectar a la capacidad del participante para completar el estudio.
    9.Está tomando inhibidores de la proteasa del VIH (como ritonavir en dosis bajas), pautas con cobicistat, elvitegravir, efavirenz, etravirina o nevirapina. Los participantes que estén recibiendo TAR prohibidos podrán cambiar a un tratamiento aceptado entre la selección y el momento basal. Deberán haber recibido el nuevo TAR al menos 14 días antes de la recogida de muestras de swlwccion. La visita basal debe de ser completada una vez que todos los
    resultados analíticos de selección están disponibles y revisados
    10.Está recibiendo otro tratamiento concomitante no compatible con vesatolimod. Los participantes que estén recibiendo medicamentos no compatibles en la selección (por ejemplo, atorvastatina, inhibidores de la bomba de protones) podrán cambiar de tratamiento. Deberán haber suspendido los medicamentos no compatibles al menos 30 días antes de la primera dosis de vesatolimod.
    11.Ha recibido vacunas aprobadas en las 2 semanas previas a la entrada en el estudio o se ha vacunado previamente con cualquier inmunógeno experimental en los 2 años previos.
    12.Recibirá cualquier vacuna en las 4 semanas previas o 2 semanas después de cualquiera de las administraciones previstas de CCMM o en la semana en que se administre vesatolimod.
    13.Tiene antecedentes de anafilaxia o una reacción adversa grave a las vacunas.
    14.Ha recibido hemoderivados en los 6 meses previos a la selección.
    15.Ha recibido tratamiento por cáncer o enfermedad linfoproliferativa en el año previo a la selección.
    16.Ha recibido cualquier otro tratamiento actual o previo en los 30 días previos a la visita de selección que, de acuerdo con los investigadores o el promotor, hace que el participante no sea adecuado para el estudio o influiría en los resultados del estudio.
    17.Toma o ha tomado (en los 3 meses previos a la visita de selección) interferones o corticoesteroides sistémicos u otros inmunodepresores (se permite el uso de esteroides inhalados para enfermedades pulmonares o de esteroides tópicos para enfermedades cutáneas localizadas).
    18.Presenta anomalías en las siguientes pruebas analíticas realizadas durante la selección:
    •Hemoglobina 11 g/dl (mujeres) o 11,5 g/dl (hombres).
    •Recuento absoluto de neutrófilos ≤1000/mm3 (≤1 ×10^9/L)
    •Recuento absoluto de linfocitos ≤600/mm3 (≤0.6 ×10^9/L)
    Plaquetas ≤100,000/mm3 or ≥550,000/mm3 (≤100 x10^3/µL or ≥550x10^3/µL)
    Bioquímica clínica
    •Creatinina >1,3 veces el límite superior de la normalidad (LSN)
    •Aspartato aminotransferasa <2,5 veces el LSN
    •Alanina aminotransferasa >2,5 veces el LSN
    Microbiología
    •Antígeno de superficie del virus de la hepatitis B.
    •Muestra positividad en anticuerpos contra el virus de la hepatitis C, a menos que se confirme la eliminación de la infección por el virus de la hepatitis C (espontánea o después de tratamiento) determinada por una reacción en cadena de la polimerasa negativa para el virus de la hepatitis C en suero.
    •Presenta serología indicativa de sífilis activa con necesidad de tratamiento. El periodo de selección de hasta 45 días debería ser suficiente para los participantes tratados por sífilis.
    19.No está dispuesto a someterse a una ITA conforme a lo previsto durante el estudio.
    20.No es apto para ser incluido en el estudio basándose en el criterio del investigador o del promotor.
    21.Abuso actual de alcohol, drogas o sustancias, o antecedentes de tal abuso en los 6 meses previos a la selección.
    E.5 End points
    E.5.1Primary end point(s)
    •Proportion of participants developing solicited Grade 3 or 4 local reactions
    •Proportion of participants developing solicited Grade 3 or 4 systemic reactions
    •Proportion of participants developing SAEs (Serious Adverse Events)
    Proporción de participantes con reacciones locales de grado 3 ó 4 solicitadas.
    Proporción de participantes con reacciones sistémicas de grado 3 ó 4 solicitadas.
    Proporción de participantes con AAG ( Acontecimientos Adversos Graves)
    E.5.1.1Timepoint(s) of evaluation of this end point
    In the 7 days period following administration of IMPs during period 1.
    En el período de 7 días después de la administración de IMPs durante el período 1.
    E.5.2Secondary end point(s)
    Safety
    a) Proportion of participants developing treatment-emergent adverse event (TEAEs) during period 1.
    b)Proportion of participants developing TEAEs after period 1
    c)Proportion of participants developing SAEs after period 1
    d) Proportion of participants who achieve virologic suppression (<50 copies/mL) after resumption of ART at week 84.

    Efficacy
    a) Proportion of participants in Period 2 with viral load < 50 copies/mL below at week 12 and 24 weeks after the start of analytical treatment interruption (ATI)
    b) Proportion of participants in Period 2 with viral load <2000 copies/mL at 12 and 24 weeks after the start of ATI.
    c) Proportion of participants in Period 2 that remain off antiretroviral therapy (ART) at 12 and 24 weeks after the start of ATI
    d)Time to plasma viral load [pVL] ≥50 copies/mL during ATI for participants in Period 2
    e)Time to pVL ≥10,000 copies/mL) during ATI for participants in Period 2
    f)Time to ART resumption from the start of ART interruption for participants in Period 2

    Immunogenicity:
    •Proportion of participants with de-novo T cell responses to HTI encoded regions during Period 1 as determined by IFN gamma enzyme-linked immunospot (ELISPOT) assay
    •Breadth and magnitude of total vaccine-induced HIV-1 specific T cell responses during Period 1 as measured by IFN gamma ELISPOT
    Seguridad
    a)Proporción de participantes con eventos adversos emergente del tratamiento (TEAEs) en el periodo 1.
    b)Proporción de participantes con TEAEs tras el periodo 1.
    c)Proporción de participantes con AAG tras el periodo 1.
    d)Proporción de participantes que logran la supresión virológica (<50 copias/ml) tras reanudar el TAR en la semana 84.
    Eficacia
    •Proporción de participantes en el periodo 2 con una concentración vírica <50 copias/ml a las 12 y 24 semanas tras el inicio de la ITA.
    •Proporción de participantes en el periodo 2 con una concentración vírica <2000 copias/ml a las 12 y 24 semanas tras el inicio de la ITA.
    •Proporción de participantes en el periodo 2 que siguen sin TAR a las 12 y 24 semanas tras el inicio de la ITA.
    •Tiempo hasta una concentración vírica plasmática (CVP) ≥50 copias/ml durante la ITA en los participantes en el periodo 2.
    •Tiempo hasta una CVP ≥10.000 copias/ml durante la ITA en los participantes en el periodo 2.
    •Tiempo hasta la reanudación del TAR desde el inicio de la interrupción del TAR en los participantes en el periodo 2.
    Inmunogenicidad
    •Proporción de participantes con respuestas de novo de linfocitos T a regiones codificadas de HTI durante el periodo 1 de acuerdo con el análisis ELISPOT (enzimoinmunotransferencia) de IFNγ.
    •Amplitud y magnitud de las respuestas totales del linfocito T específico del VIH 1 inducidas por las vacunas durante el periodo 1 determinado por ELISPOT de IFNγ.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Safety a,b, c: After Period 1. d) after resumption of ART
    Efficacy: in period 2
    Immunology: during period 1
    Seguridad a, b, c: Después del Período 1. d) tras la reanudación del TAR
    Eficacia: en el período 2
    Inmunología: durante el periodo 1
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Immunogenicity
    Inmunogenicidad
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned8
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LPLV includes the follow up visit
    La ultima Visita del ultimo paciente incluye la visita de seguimiento
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 57
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state57
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 57
    F.4.2.2In the whole clinical trial 57
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Physician will determine the appropriate antiretroviral therapy for each subject out of the trial
    El médico determinará la terapia antirretroviral adecuada para cada sujeto fuera del ensayo
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-05-09
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-02-18
    P. End of Trial
    P.End of Trial StatusRestarted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 20:47:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA